<DOC>
	<DOCNO>NCT00554125</DOCNO>
	<brief_summary>The purpose study evaluate influence sirolimus outcome OLT HCC exceed Milan criterion .</brief_summary>
	<brief_title>Sirolimus-Based Immunosuppression Therapy OLT Patients With HCC Exceeding Milan Criteria</brief_title>
	<detailed_description>Hepatocellular carcinoma ( HCC ) one prevalent cancer Asia Africa . Although first-line therapy HCC liver resection , concomitant cirrhosis often leave orthotopic liver transplantation ( OLT ) rather liver resection potentially curative option . The risk recurrence major concern patient transplant HCC . It demonstrate utilize restrictive selection criterion submit cirrhotic patient HCC liver transplantation associate well outcome . The Milan criterion ( one nodule ≤5 cm 2-3 nodule ＜3 cm , without macroscopic vascular invasion extrahepatic spreading ) provide simple mean select patient HCC transplantation low risk ( ≈10 % ) recurrence . However , benefit OLT patient HCC within Milan criterion oppose critical organ shortage , lengthen wait time thus allow tumor progression wait period . Nearly one third patient transplant HCC fall outside Milan criteria basis pathological finding explanted liver , high risk tumor recurrence.This lead dramatic decline overall disease-free survival , 71-85 % 40-50 % , 65-78 % 27-30 % , respectively . Although hypothesized pharmacologic immunosuppression require liver transplantation HCC may accelerate tumor recurrence metastasis , recent report suggest immunosuppressive drug necessarily promote HCC recurrence transplant recipient . Sirolimus emerge new , potent immunosuppressive agent unlike immunosuppressant [ cyclosporine ( CsA ) , tacrolimus ( FK506 ) , azathioprine ( AZA ) ] potent antitumor activity vitro vivo . The immunosuppressive antitumor effect sirolimus share common mechanism action . Sirolimus inhibit mammalian target sirolimus ( mTOR ) , prevents acute graft rejection mediate interleukin-2 could block cytokine signal transduction , thus directly inhibit tumor cell proliferation angiogenesis . And important antitumor activity SRL show concentration maintenance target level posttransplant patient . Thus , seem reasonable speculate sirolimus could simultaneously contribute inhibition tumor recurrence prevent rejection OLT patient HCC .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>The major organ ( liver , heart , lung kidney ) function OLT normal . Pathologically prove HCC randomisation . Tumor exceed Milan criterion ( one nodule ≤5 cm 23 nodule ＜3 cm , without macroscopic vascular invasion extrahepatic spreading ) . Signed , write informed consent . Extrahepatic metastasis , nodal involvement , perioperative death ( within 30 day operation ) , tumor thrombus proximal main trunk portal vein / vena cava History cardiac disease . Active clinically serious infection ( ＞grade 2 Nation Cancer Institute NCICTCAE version 3.0 ) . Known history human immunodeficiency virus ( HIV ) infection . Any condition unstable could jeopardize safety patient / compliance study . Pregnant breastfeeding patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Sirolimus ; Orthotopic liver transplantation ; HCC</keyword>
</DOC>